Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

References

• Kilgore PE, Salim AM, Zervos MJ, et al. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449–486.
   PubMed Web of Science ®Google Scholar
• Nieves DJ, Heininger U. Bordetella pertussis. Microbiol Spectr. 2016 Jun;4(3). doi:10.1128/microbiolspec.EI10-0008-2015. PMID: 27337481
   Google Scholar
• CDC. Centers for diseases control and prevention: pertussis (Whooping Cough) surveillance and reporting. (Ed.^(Eds) (2019)
   Google Scholar
• Cherry JD. Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785–787.
   PubMed Web of Science ®Google Scholar
• Gale JL, Thapa PB, Wassilak SG, et al. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study. JAMA. 1994;271(1):37–41.
   PubMed Web of Science ®Google Scholar
• Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J. 2006;25(9):768–773.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984;1(8369):122–126.
   PubMed Web of Science ®Google Scholar
• Klein NP. Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014;10(9):2684–2690.
   PubMed Web of Science ®Google Scholar
• Latasa P, Garcia-Comas L, Gil De Miguel A, et al. Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015. Vaccine. 2018;36(12):1643–1649.
   PubMed Web of Science ®Google Scholar
• Bell CA, Russell ML, Drews SJ, et al. Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010-2015, a Canadian Immunization Research Network (CIRN) study. Vaccine. 2019;37(30):4140–4146.
   PubMed Web of Science ®Google Scholar
• Guris D, Strebel PM, Jafari H, et al. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR–7):1–25.
   Google Scholar
• Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR–3):1–34.
   PubMedGoogle Scholar
• Skoff TH, Martin SW. Impact of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: a follow-up analysis. JAMA Pediatr. 2016;170(5):453–458.
   PubMed Web of Science ®Google Scholar
• Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1–44.
   PubMed Web of Science ®Google Scholar
• World, Health, Organization. Global Immunization 1980–2019: global coverage from 3 doses of DTP containing vaccine. Accessed April 2021. (Ed.^(Eds))
   Google Scholar
• Data Management Division, National Immunization Program, Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months–United States, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(30):637–641.
   PubMedGoogle Scholar
• Hill HA, Elam-Evans LD, Yankey D, et al. National, state, and selected local area vaccination coverage among children aged 19-35 months - United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(33):889–896.
   PubMed Web of Science ®Google Scholar
• Hill HA, Yankey D, Elam-Evans LD, et al. Vaccination coverage by age 24 months among children born in 2016 and 2017 - National Immunization Survey-Child, United States, 2017-2019. MMWR Morb Mortal Wkly Rep. 2020;69(42):1505–1511.
   PubMed Web of Science ®Google Scholar
• Krishnarajah G, Malangone-Monaco E, Palmer L, et al. Age-appropriate compliance and completion of up to five doses of pertussis vaccine in US children. Hum Vaccin Immunother. 2018;14(12):2932–2939.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–723.
   PubMed Web of Science ®Google Scholar
• Choi YH, Campbell H, Amirthalingam G, et al. Investigating the pertussis resurgence in England and Wales, and options for future control. BMC Med. 2016;14(1):121.
   PubMed Web of Science ®Google Scholar
• Amirthalingam G. Strategies to control pertussis in infants. Arch Dis Child. 2013;98(7):552–555.
   PubMed Web of Science ®Google Scholar
• Khetsuriani N, Bisgard K, Prevots DR, et al. Pertussis outbreak in an elementary school with high vaccination coverage. Pediatr Infect Dis J. 2001;20(12):1108–1112.
   PubMed Web of Science ®Google Scholar
• Matthias J, Pritchard PS, Martin SW, et al. Sustained transmission of pertussis in vaccinated, 1-5-year-old children in a preschool, Florida, USA. Emerg Infect Dis. 2016;22(2):242–246.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Prevention of pertussis: an unresolved problem. Hum Vaccin Immunother. 2018;14(10):2452–2459.
   PubMed Web of Science ®Google Scholar
• Esposito S, Stefanelli P, Fry NK, et al. Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines. Front Immunol. 2019;10:1344.
   PubMed Web of Science ®Google Scholar
• Winter K, Zipprich J, Harriman K. Pertussis in California: a Tale of 2 Epidemics. Pediatr Infect Dis J. 2018;37(4):324–328.
   PubMed Web of Science ®Google Scholar
• Mink CM, Yeh SH. Pertussis in adolescents and its prevention using Tdap vaccination. Adolesc Med State Art Rev. 2010;21(2):220–235, viii.
   PubMedGoogle Scholar
• Klein NP, Bartlett J, Fireman B, et al. Waning Tdap effectiveness in adolescents. Pediatrics. 2016;137(3):e20153326.
   PubMed Web of Science ®Google Scholar
• Klein NP, Zerbo O. Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017;16(12):1175–1179.
   PubMed Web of Science ®Google Scholar
• Pillsbury A, Quinn HE, McIntyre PB. Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012. Commun Dis Intell Q Rep. 2014;38(3):E179–194.
   PubMedGoogle Scholar
• Skoff TH, Hadler S, Hariri S. The epidemiology of Nationally reported pertussis in the United States, 2000-2016. Clin Infect Dis. 2019;68(10):1634–1640.
   PubMed Web of Science ®Google Scholar
• European Centers for Disease Control. Pertussis Annual Epidemiological Report for 2018. cited 2021 Aug 31. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_pertussis.pdf
   Google Scholar
• Yeung KHT, Duclos P, Nelson EAS, et al. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017;17(9):974–980.
   PubMed Web of Science ®Google Scholar
• Redlberger-Fritz M, Kundi M, Aberle SW, et al. Significant impact of nationwide SARS-CoV-2 lockdown measures on the circulation of other respiratory virus infections in Austria. J Clin Virol. 2021 Apr;137:104795.
   PubMedGoogle Scholar
• Kuitunen I, Artama M, Makela L, et al. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020;39(12):e423–e427.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect Dis Ther. 2021 Aug 26:1–48.
   Web of Science ®Google Scholar
• Tan T, Dalby T, Forsyth K, et al. Pertussis across the globe: recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J. 2015;34(9):e222–232.
   PubMed Web of Science ®Google Scholar
• Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39(11):1572–1580.
   PubMed Web of Science ®Google Scholar
• Varan AK, Harriman KH, Winter K, et al. Economic and social impact of pertussis among adolescents in San Diego County. J Adolesc Health. 2016;58(2):241–244.
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293–299.
   PubMed Web of Science ®Google Scholar
• Skoff TH, Kenyon C, Cocoros N, et al. Sources of infant pertussis infection in the United States. Pediatrics. 2015;136(4):635–641.
   PubMed Web of Science ®Google Scholar
• Damron FH, Barbier M, Dubey P, et al. Overcoming waning immunity in pertussis vaccines: workshop of the national institute of allergy and infectious diseases. J Immunol. 2020;205(4):877–882.
   PubMed Web of Science ®Google Scholar
• Cherry JD. The 112-year odyssey of pertussis and pertussis vaccines-mistakes made and implications for the future. J Pediatric Infect Dis Soc. 2019;8(4):334–341.
   PubMed Web of Science ®Google Scholar
• Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis. 2014;209(Suppl 1):S32–35.
   PubMed Web of Science ®Google Scholar
• Quinn HE, Snelling TL, Macartney KK, et al. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics. 2014;133(3):e513–519.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine. 2017;35(26):3395–3400.
   PubMed Web of Science ®Google Scholar
• Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126–2132.
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei R, Moradi-Lakeh M, Shakerian S, et al. Acellular pertussis vaccine efficacy: an updated systematic review and meta -analysis. Med J Islam Repub Iran. 2016;30:451.
   PubMedGoogle Scholar
• Zerbo O, Bartlett J, Goddard K, et al. Acellular pertussis vaccine effectiveness over time. Pediatrics. 2019;144(1):e20183466.
   PubMed Web of Science ®Google Scholar
• Chit A, Zivaripiran H, Shin T, et al. Acellular pertussis vaccines effectiveness over time: a systematic review, meta-analysis and modeling study. PLoS One. 2018;13(6):e0197970.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012–1019.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047–1052.
   PubMed Web of Science ®Google Scholar
• Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135(6):981–989.
   PubMed Web of Science ®Google Scholar
• Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942–953.
   PubMed Web of Science ®Google Scholar
• Conway JH, Davis JP, Eickhoff JC, et al. Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014. Vaccine. 2020;38(45):7063–7069.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787–792.
   PubMed Web of Science ®Google Scholar
• Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun. 2001;69(7):4516–4520.
   PubMed Web of Science ®Google Scholar
• Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 2015;13:146.
   PubMedGoogle Scholar
• Williams MM, Sen K, Weigand MR, et al. Bordetella pertussis strain lacking pertactin and pertussis toxin. Emerg Infect Dis. 2016;22(2):319–322.
   PubMed Web of Science ®Google Scholar
• Van Gent M, Heuvelman CJ, van der Heide HG, et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur J Clin Microbiol Infect Dis. 2015;34(4):821–830.
   PubMed Web of Science ®Google Scholar
• Bouchez V, Hegerle N, Strati F, et al. new data on vaccine antigen deficient Bordetella pertussis isolates. Vaccines (Basel). 2015;3(3):751–770.
   PubMed Web of Science ®Google Scholar
• Cabal A, Schmid D, Hell M, et al. Isolate-based surveillance of Bordetella pertussis, Austria, 2018-2020. Emerg Infect Dis. 2021;27(3):862–871.
   PubMed Web of Science ®Google Scholar
• Dewan KK, Linz B, DeRocco SE, et al. Acellular pertussis vaccine components: today and tomorrow. Vaccines (Basel). 2020;8(2):217.
   Web of Science ®Google Scholar
• Breakwell L, Kelso P, Finley C, et al. pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis. Pediatrics. 2016;137(5):e20153973.
   PubMed Web of Science ®Google Scholar
• Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect. 2014;142(4):685–694.
   PubMed Web of Science ®Google Scholar
• America Academy of Pediatrics Commitee on Infectious D. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117(3):965–978.
   PubMed Web of Science ®Google Scholar
• Healy CM, Rench MA, Wootton SH, et al. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015;34(1):22–26.
   PubMed Web of Science ®Google Scholar
• Castagnini LA, Healy CM, Rench MA, et al. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis. 2012;54(1):78–84.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months — advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(41):1424–1426.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention, Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women–Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131–135.
   PubMed Web of Science ®Google Scholar
• Mazzilli S, Tavoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect newborns from pertussis infection. Ann Ig. 2018;30(4):346–363.
   PubMed Web of Science ®Google Scholar
• Brousseau N, Gagnon D, Vivion M, et al. Expected challenges of implementing universal pertussis vaccination during pregnancy in Quebec: a cross-sectional survey. CMAJ Open. 2018;6(3):E391–E397.
   PubMedGoogle Scholar
• Campbell H, Gupta S, Dolan GP, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. J Med Microbiol. 2018;67(10):1426–1456.
   PubMed Web of Science ®Google Scholar
• Kong KL, Krishnaswamy S, Giles ML. Maternal vaccinations. Aust J Gen Pract. 2020;49(10):630–635.
   PubMed Web of Science ®Google Scholar
• Vizzotti C, Neyro S, Katz N, et al. Maternal immunization in Argentina: a storyline from the prospective of a middle income country. Vaccine. 2015;33(47):6413–6419.
   PubMed Web of Science ®Google Scholar
• Kandeil W, van den Ende C, Bunge EM, et al. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Rev Vaccines. 2020;19(7):621–638.
   PubMed Web of Science ®Google Scholar
• Winter K, Nickell S, Powell M, et al. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017;64(1):3–8.
   PubMed Web of Science ®Google Scholar
• Langsam D, Anis E, Haas EJ, et al. Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis. Vaccine. 2020;38(12):2700–2706.
   PubMed Web of Science ®Google Scholar
• Carrasquilla G, Porras A, Martinez S, et al. Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogota, Colombia. Vaccine. 2020;38(46):7384–7392.
   PubMed Web of Science ®Google Scholar
• Vizzotti C, Juarez MV, Bergel E, et al. Impact of a maternal immunization program against pertussis in a developing country. Vaccine. 2016;34(50):6223–6228.
   PubMed Web of Science ®Google Scholar
• Sebghati M, Khalil A. Uptake of vaccination in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2021 Apr 6:S1521-6934(21)00046-8. doi:10.1016/j.bpobgyn.2021.03.007. Epub ahead of print. PMID: 33965331; PMCID: PMC8021457
   Google Scholar
• Boulet SL, Chamberlain AT, Biswas HH, et al. Trends in Infant Pertussis Hospitalizations in the United States, 2009-2017. JAMA. 2019;322(21):2134–2136.
   PubMed Web of Science ®Google Scholar
• Fernandes EG, Sato APS, Vaz-de-Lima LRA, et al. The effectiveness of maternal pertussis vaccination in protecting newborn infants in Brazil: a case-control study. Vaccine. 2019;37(36):5481–5484.
   PubMed Web of Science ®Google Scholar
• Romanin V, Acosta AM, Juarez MDV, et al. Maternal vaccination in Argentina: tetanus, diphtheria, and acellular pertussis vaccine effectiveness during pregnancy in preventing pertussis in infants <2 months of age. Clin Infect Dis. 2020;70(3):380–387.
   PubMed Web of Science ®Google Scholar
• Baxter R, Bartlett J, Fireman B, et al. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139(5):e20164091.
   PubMed Web of Science ®Google Scholar
• Razzaghi H, Kahn KE, Black CL, et al. Influenza and Tdap vaccination coverage among pregnant women - United States, April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1391–1397.
   PubMed Web of Science ®Google Scholar
• Greenfield I, Wu D, Anderson M, et al. Electronic medical record intervention to improve adherence to prenatal vaccination recommendation [12F]. Obstetrics Gynecol. 2019;133:65S.
   Google Scholar
• Wong VW, Lok KY, Tarrant M. Interventions to increase the uptake of seasonal influenza vaccination among pregnant women: a systematic review. Vaccine. 2016;34(1):20–32.
   PubMed Web of Science ®Google Scholar
• Bisset KA, Paterson P. Strategies for increasing uptake of vaccination in pregnancy in high-income countries: a systematic review. Vaccine. 2018;36(20):2751–2759.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Halperin SA, Nolan T, et al. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: follow-up of a randomized trial. Vaccine. 2021;39(11):1598–1608.
   PubMed Web of Science ®Google Scholar
• Perrett KP, Halperin SA, Nolan T, et al. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine. 2020;38(8):2105–2114.
   PubMed Web of Science ®Google Scholar
• Vaz-de-Lima LRA, Sato APS, Pawloski LC, et al. Effect of maternal Tdap on infant antibody response to a primary vaccination series with whole cell pertussis vaccine in Sao Paulo, Brazil. Vaccine. 2021;7:100087.
   Web of Science ®Google Scholar
• Wanlapakorn N, Maertens K, Vongpunsawad S, et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clin Infect Dis. 2020;71(1):72–80.
   PubMed Web of Science ®Google Scholar
• Wodi AP, Ault K, Hunter P, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(6):189–192.
   PubMed Web of Science ®Google Scholar
• National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 28;60(2):1-64. Erratum in: MMWR Recomm Rep. 2011 Jul 29;60:993. PMID: 21293327.
   Google Scholar
• Bugenske E, Stokley S, Kennedy A, et al. Middle school vaccination requirements and adolescent vaccination coverage. Pediatrics. 2012;129(6):1056–1063.
   PubMed Web of Science ®Google Scholar
• Kamiya H, Cho BH, Messonnier ML, et al. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. Vaccine. 2016;34(15):1832–1838.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Abbasi J. COVID-19 and mRNA vaccines-first large test for a new approach. JAMA. 2020;324(12):1125–1127.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv. 2021:2021.08.03.21261496. doi:10.1101/2021.08.03.21261496
   Google Scholar
• Dorji D, Mooi F, Yantorno O, et al. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. Med Microbiol Immunol. 2018;207(1):3–26.
   PubMed Web of Science ®Google Scholar
• Jahnmatz M, Richert L, Al-Tawil N, et al. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis. 2020;20(11):1290–1301.
   PubMed Web of Science ®Google Scholar
• Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine–BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014;9(1):e83449.
   PubMed Web of Science ®Google Scholar